# Multiple Myeloma Public Review Release Gate Pass v0

Stewarded by [frg.earth](https://frg.earth/).

- disease program: `multiple-myeloma`
- artifact id: `multiple-myeloma-public-review-release-gate-pass-v0`
- claim level: open-question
- gate input: [Public Review And Release Gate v0](public-review-release-gate-v0.md)
- pass status: repository-release review pass
- clinical boundary: research-use-only, not medical advice
- release boundary: main-merge readiness only, not clinical or scientific
  authorization
- last reviewed: `2026-04-15`

## Purpose

This pass records the first maintainer/operator review of the public
multiple myeloma v0 artifact surface after the autonomous loop completion
handoff and release gate were added.

It answers one narrow repository question:

Can the current public artifacts move through normal pull-request review as
public research infrastructure while preserving the public/private boundary,
claim limitations, provenance requirements, and frg.earth stewardship mark?

It does not answer whether any scientific claim is expert-reviewed, complete,
clinically actionable, or ready for patient-facing guidance.

## Gate Decision

Repository decision: `ready-for-maintainer-review`.

Recommended repository action: mark the pull request ready for maintainer
review after validation passes, then merge only through protected-branch
checks.

Not authorized by this pass:

- public announcement that implies a cure, vaccine, treatment, trial, or
  eligibility pathway
- patient-specific case intake or case upload
- generated biomedical claims
- generated review packets
- target, therapy, trial, source, mechanism, evidence, or artifact ranking
- clinical use, diagnostic use, treatment use, trial guidance, or
  expanded-access guidance
- publication of case-derived learning

## Review Lane Results

| Lane | Result | Basis | Remaining Human Work |
| --- | --- | --- | --- |
| Public safety | operator pass for repository merge | Public artifacts state research-use-only boundaries, contain no real case data by design, and preserve no-PHI, no-credentials, and no-patient-advice rules. | Re-check before release notes, public announcement, or any new export. |
| Scientific provenance | operator pass for modest infrastructure framing | Artifacts carry source IDs, subtype scope, claim levels, and limitations. Review packets still mark claim language as `expert-review-needed`. | Qualified myeloma review is still needed before stronger scientific or patient-facing language. |
| Patient/public readability | operator pass with inventory support | The companion inventory gives a plain public map of what exists and what it is not. | Patient/caregiver advocate review is still needed before public explainers. |
| Engineering integrity | operator pass pending current validation | The current branch has cataloged metadata, route-table self-test coverage, zero ready public tasks after loop completion, and a protected-branch PR path. | Re-run validation after every edit and before merge. |
| Stewardship | operator pass for current surface | frg.earth stewardship appears on the program and gate artifacts, and the public/private boundary is explicit. | Keep the stewardship mark on downstream public artifacts and release notes. |

## Checks To Record Before Merge

Record these checks in the pull request before marking it ready:

1. `make validate`
2. `make review-packet-route-table ARGS="--self-test"`
3. `make list-public-artifacts ARGS="--scope myeloma"`
4. `make list-public-tasks ARGS="--status ready"`
5. `make list-review-packets`
6. `git diff --check`
7. `git status --ignored --short`
8. A public-boundary scan for patient identifiers, credentials, and private
   case-language patterns

## Current Public Surface

The companion [Public Inventory v0](public-inventory-v0.md) is the
human-readable summary of the current public surface.

The inventory should be treated as the current-state map for PR review. It
does not replace source review, expert review, or clinical review.

## Merge Framing

Acceptable merge framing:

- public multiple myeloma research infrastructure
- public-safe case-to-cure plumbing
- source-backed maps, schemas, gates, and review-readiness artifacts
- validated public artifact catalog and navigation
- no real case data
- no medical advice

Unacceptable merge framing:

- cure found
- vaccine found
- treatment recommendation
- trial recommendation
- patient matching
- target prioritization
- therapy ranking
- expert-reviewed clinical conclusion
- patient-facing guidance
- publication-ready case-derived result

## Post-Merge Next Phase

After merge, the next public-safe phase should be one of:

- expert-review packet outreach and issue creation
- source-backed map expansion with a new named gate
- plain-language review of existing boundaries and limitations
- synthetic-data-only tooling checks that do not generate clinical claims
- private-lab handoff work outside this public repo

Do not restart autonomous public work until a new named phase has a clear
aggregate gate and task model.

## Public Safety Check

- No patient-identifying data.
- No real case data.
- No private records.
- No credentials, paid APIs, account changes, or restricted datasets.
- No patient-specific diagnosis, prognosis, treatment, trial, expanded-access,
  monitoring, or candidate-option guidance.
- No target, therapy, trial, source, mechanism, artifact, task, or evidence
  ranking.
- No generated biomedical claims.
- No expert-review substitution.
- No publication authorization.
- No cure or vaccine claim.

## Limitations

- This pass is a repository-readiness artifact, not expert review.
- This pass does not prove source coverage is comprehensive.
- This pass does not verify any real case, private record, trial site,
  sponsor pathway, clinician decision, regulatory decision, institutional
  decision, or publication decision.
- This pass does not authorize patient-specific work in the public repo.
- This pass does not authorize public case uploads, public case processing, or
  public case-derived publication.
- This pass does not authorize generated claims, generated review packets,
  recommendation behavior, matching behavior, ranking behavior, or clinical
  workflow.
- This pass does not provide medical advice, diagnostic guidance, treatment
  guidance, trial guidance, eligibility guidance, expanded-access guidance,
  monitoring guidance, or a cure claim.
